<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883181</url>
  </required_header>
  <id_info>
    <org_study_id>20060445</org_study_id>
    <nct_id>NCT00883181</nct_id>
  </id_info>
  <brief_title>A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy</brief_title>
  <official_title>A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to describe the incidence of febrile neutropenia based on
      granulocyte-colony stimulating factor (G-CSF) use (primary, secondary, treatment, or no
      usage) in patients receiving myelotoxic chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center international observational study of patients receiving myelotoxic
      regimens, with an investigator assessed risk of febrile neutropenia ≥ 20%, for the treatment
      of solid tumors (breast, ovarian and lung).

      This is an observational study in which patient risk factors were qualitatively (but not
      quantitatively) assessed, and adherence to G-CSF primary prophylaxis was at the discretion of
      physicians and not mandated by the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Febrile Neutropenia (FN)</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>Febrile neutropenia was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm².</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Received No Prophylaxis or Treatment With Granulocyte Colony-stimulating Factors (G-CSF) Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants in the No G-CSF use group received no G-CSF prophylaxis or treatment at any time during cycles 1 to 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Primary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis with pegfilgrastim was defined as receiving pegfilgrastim starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the 'best' G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of Cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Primary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis was defined as receiving any daily G-CSF (e.g. filgrastim or lenograstim) starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the 'best' G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Secondary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis with pegfilgrastim was defined as receiving pegfilgrastim starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the 'best' G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of pegfilgrastim support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Secondary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis was defined as receiving any daily G-CSF starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the 'best' G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of G-CSF support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Primary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis was defined as receiving any other G-CSF starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the 'best' G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Secondary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis was defined as receiving any daily G-CSF starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the 'best' G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of G-CSF support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Treatment With Pegfilgrastim Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with pegfilgrastim is defined as participants who started pegfilgrastim treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Treatment With Any Daily G-CSF Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with any daily G-CSF is defined as participants who started daily G-CSF treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Treatment With Any Other G-CSF Who Experienced Febrile Neutropenia</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with any other G-CSF is defined as participants who started other G-CSF treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received G-CSF During Cycles 1 to 8</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Pegfilgrastim</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Any Daily G-CSF</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The average number of days of daily G-CSF use per cycle was calculated across all administered cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Pegfilgrastim</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Any Daily G-CSF</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The average number of days of daily G-CSF use per cycle was calculated across all administered cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Treatment in Participants Receiving Treatment With Pegfilgrastim</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Treatment in Participants Receiving Treatment With Any Daily G-CSF</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chemotherapy Dose Delays in Cycles 2 Through 8</measure>
    <time_frame>Cycles 2 - 8 (approximately 21 weeks)</time_frame>
    <description>A dose delay is defined as a delay of more than 3 days in the start of chemotherapy measured since the start of the previous cycle. The percentage of participants with delays in chemotherapy administration are summarized by the length of delay (&gt; 3 days, &gt; 5 days, and &gt; 7 days) across cycles 2 through 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cycles With Chemotherapy Dose Delays</measure>
    <time_frame>Cycles 2 - 8 (approximately 21 days)</time_frame>
    <description>A dose delay is defined as a delay of &gt; 3 days in the start of chemotherapy measured since the start of the previous cycle. The percentage of cycles delayed are summarized by the length of delay (&gt; 3 days, &gt; 5 days, and &gt; 7 days) across cycles 2 through 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chemotherapy Dose Reductions</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>A participant is considered to have a dose reduction in a given cycle if there was a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cycles With Chemotherapy Dose Reductions</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>A dose reduction in a given cycle is defined as a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Cycles With &gt; 3 Days Chemotherapy Dose Delays in Cycles 2 to 8</measure>
    <time_frame>Cycles 2 - 8 (approximately 21 weeks)</time_frame>
    <description>A dose delay is defined as a delay of &gt; 3 days in the start of chemotherapy measured since the start of the previous cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Cycles With ≥ 15% Chemotherapy Dose Reductions in Cycles 1-8</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>A dose reduction in a given cycle is defined as a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Anti-infective Use in Cycles 1 to 8</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>Number of participants with systemic anti-infective use, including antibiotics, anti-fungal and virostatic for prophylaxis or treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unplanned Hospitalizations</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>Unplanned hospitalizations included only those which involved an overnight stay and occurred in cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessed Clinical Response at End of Treatment</measure>
    <time_frame>End of treatment (approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematological Toxicities</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The number of participants experiencing treatment related grade 3 and 4 hematological toxicities during cycles 1 to 8. Participants experiencing both Grade 3 and Grade 4 toxicities are reported under Grade 4 only (maximum toxicity). Toxicity grades for hematology data are defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0: Absolute neutrophil count (ANC) - Grade 3: &lt; 1.0 - 0.5 x 10^9/L; ANC - Grade 4: &lt; 0.5 x 10^9/L; White blood cells (WBC) - Grade 3: &lt; 2.0 - 1.0 x 10^9/L; WBC - Grade 4: &lt; 1.0 x 10^9/L; Hemoglobin - Grade 3: &lt; 8.0 - 6.5 g/dL; Hemoglobin - Grade 4: &lt; 6.5 g/dL; Platelets - Grade 3: &lt; 50 - 25 x 10^9/L; Platelets - Grade 4: &lt; 25 x 10^9/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>From cycle 1, day 1 until end of the long-term follow-up; median time on follow-up from cycle 1, day 1 was 52 months.</time_frame>
    <description>Time to disease progression was calculated from cycle 1 day 1 to a date at which disease progression was first recorded. Participants who died due to causes other than disease progression were censored at the date of death. Participants who were alive and whose disease had not progressed at the most recent contact, or who were lost to follow-up, or with missing data, were censored at the date of last contact. Median time to disease progression was estimated from the Kaplan-Meier survival function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment With Erythropoiesis-stimulating Agents (ESAs)</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for Treatment With Erythropoiesis-stimulating Agents</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The reason treatment with an ESA was initiated as recorded by the investigator; participants may have more than one reason for initiating treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level at Initiation of Erythropoiesis-stimulating Agent Treatment</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinical Visits in Cycles 1-8 by ESA Use</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>The average number of clinical visits per month (28 day period) during cycles 1 to 8 and during the period of ESA treatment in cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Required a Red Blood Cell (RBC) Transfusion After 5 Weeks of ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants with RBC transfusions from five weeks post initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin During ESA Treatment Phase</measure>
    <time_frame>Initiation of ESA treatment (last assessment on or prior to ESA day 1) and at end of ESA treatment; median duration of ESA treatment was 4 weeks, maximum was 23 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hematopoietic Response</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants in cycles 1 to 8 receiving ESA treatment who achieved a hematopoietic response during the ESA treatment phase, defined as a hemoglobin concentration ≥ 12 g/dL or a ≥ 2 g/dL rise in hemoglobin after starting ESA treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 9 g/dL After 5 Weeks ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 9 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 10 g/dL After 5 Weeks ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 10 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 11 g/dL After 5 Weeks ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 11 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 12 g/dL After 5 Weeks ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 12 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL After 5 Weeks ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level from 10 to 12 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 12 to 13 g/dL After 5 Weeks ESA Treatment</measure>
    <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
    <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level from 12 to 13 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL 9 Weeks After Initiation of ESA Treatment</measure>
    <time_frame>9 weeks post initiation of ESA treatment</time_frame>
    <description>The percentage of participants achieving a hemoglobin level from 10 to 12 g/dL after 9 weeks of ESA treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Transfusions in Cycles 1 to 8</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
    <description>Number of participants who received transfusions, including platelets, packed red blood cells, whole blood, or other, during cycles 1 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Transfusions Per Participant in Cycles 1 to 8</measure>
    <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1370</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      This is an observational study. No bio-specimens are being collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sites were selected based on where medical data of interest were routinely and completely
        collected. To avoid geographical bias, sites represented various types of treating centers
        within each country and sites were encouraged to provide data on patients within all tumor
        types.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects greater than or equal to 18 years old with breast, ovarian or lung cancer
             receiving chemotherapy in any schedule, e.g. dose dense or standard chemotherapy.

          -  These subjects must have an Investigator assessed risk of febrile neutropenia (FN)
             ≥20% (based on 2006 European Organisation for Research and Treatment of Cancer (EORTC)
             G-CSF Guidelines

        Exclusion Criteria:

        - Subjects with concurrent administration of radiotherapy are not eligible (previous
        radiotherapy is permitted if terminated at least 2 weeks prior to commencing applicable
        chemotherapy in this study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Mäenpää J, Varthalitis I, Erdkamp F, Trojan A, Krzemieniecki K, Lindman H, Bendall K, Vogl FD, Verma S. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study. Breast. 2016 Feb;25:27-33. doi: 10.1016/j.breast.2015.11.007. Epub 2015 Dec 20.</citation>
    <PMID>26801413</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2016</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1370 patients were enrolled at 87 sites in Europe, 5 sites in Canada, and 10 sites in Australia from December 2007 to October 2009. Of these, 1347 participants were included in the full analysis set (FAS) consisting of all enrolled patients who met protocol defined eligibility criteria and started at least 1 cycle of chemotherapy.</recruitment_details>
      <pre_assignment_details>Eligible patients were enrolled sequentially. Upon completion of all planned chemotherapy cycles, or following cessation of chemotherapy for any reason, patients were followed-up annually for 5 years or until disease progression or death.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Full Analysis Set</title>
          <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1347">Full analysis set</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1069">Completed planned chemotherapy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Hematological Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-hematological Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Full Analysis Set</title>
          <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1347"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1072"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about &gt; 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair &gt; 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 – Normal Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 – Symptoms but Ambulatory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 – Confined to Bed ≤ 50% of Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 – Confined to Bed ≥ 50% of Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 – 100% Bedridden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ovarian cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-small cell lung cancer (NSCLC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small cell lung cancer (SCLC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy and radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Febrile Neutropenia Episodes</title>
          <description>Episodes of febrile neutropenia (FN) that occurred during prior cancer treatment; 698 participants had received prior treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Any prior FN episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No prior FN episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 11 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 11 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anemia Symptoms</title>
          <description>Anemia symptoms were available for 692 participants at baseline. Participants may have more than one anemia symptom.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fatigue/tiredness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor/Pale skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia and/or palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness and/or vertigo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired cognitive function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired immune system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Febrile Neutropenia (FN)</title>
        <description>Febrile neutropenia was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm².</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set; Note: One participant with breast cancer had disease stage missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Febrile Neutropenia (FN)</title>
          <description>Febrile neutropenia was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm².</description>
          <population>Full analysis set; Note: One participant with breast cancer had disease stage missing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="O3" value="15" lower_limit="10" upper_limit="21"/>
                    <measurement group_id="O4" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O5" value="11" lower_limit="6" upper_limit="19"/>
                    <measurement group_id="O6" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received G-CSF During Cycles 1 to 8</title>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received G-CSF During Cycles 1 to 8</title>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Prophylaxis - Pegfilgrastim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="360"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Prophylaxis - Any Daily G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Prophylaxis - Other G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Prophylaxis - Pegfilgrastim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Prophylaxis - Any Daily G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Prophylaxis - Other G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment - Pegfilgrastim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment - Any Daily G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment - Other G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No G-CSF Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="147"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Received No Prophylaxis or Treatment With Granulocyte Colony-stimulating Factors (G-CSF) Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants in the No G-CSF use group received no G-CSF prophylaxis or treatment at any time during cycles 1 to 8.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received no prophylaxis or treatment with any G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received No Prophylaxis or Treatment With Granulocyte Colony-stimulating Factors (G-CSF) Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants in the No G-CSF use group received no G-CSF prophylaxis or treatment at any time during cycles 1 to 8.</description>
          <population>Full analysis set participants who received no prophylaxis or treatment with any G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="147"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O4" value="1" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O5" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O6" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Primary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis with pegfilgrastim was defined as receiving pegfilgrastim starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of Cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received primary prophylaxis with pegfilgrastim</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Primary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis with pegfilgrastim was defined as receiving pegfilgrastim starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of Cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
          <population>Full analysis set participants who received primary prophylaxis with pegfilgrastim</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="360"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O2" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O3" value="21" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O4" value="9" lower_limit="7" upper_limit="13"/>
                    <measurement group_id="O5" value="9" lower_limit="3" upper_limit="24"/>
                    <measurement group_id="O6" value="9" lower_limit="7" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Primary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis was defined as receiving any daily G-CSF (e.g. filgrastim or lenograstim) starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received primary prophylaxis with any daily G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Primary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis was defined as receiving any daily G-CSF (e.g. filgrastim or lenograstim) starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
          <population>Full analysis set participants who received primary prophylaxis with any daily G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O2" value="20" lower_limit="8" upper_limit="42"/>
                    <measurement group_id="O3" value="9" lower_limit="2" upper_limit="38"/>
                    <measurement group_id="O4" value="6" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O5" value="17" lower_limit="3" upper_limit="56"/>
                    <measurement group_id="O6" value="7" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Secondary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis with pegfilgrastim was defined as receiving pegfilgrastim starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of pegfilgrastim support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received secondary prophylaxis with pegfilgrastim</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Secondary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis with pegfilgrastim was defined as receiving pegfilgrastim starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of pegfilgrastim support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
          <population>Full analysis set participants who received secondary prophylaxis with pegfilgrastim</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O2" value="36" lower_limit="16" upper_limit="61"/>
                    <measurement group_id="O3" value="40" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="O4" value="14" lower_limit="8" upper_limit="23"/>
                    <measurement group_id="O5" value="33" lower_limit="12" upper_limit="65"/>
                    <measurement group_id="O6" value="16" lower_limit="10" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Secondary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis was defined as receiving any daily G-CSF starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of G-CSF support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received secondary prophylaxis with any daily G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Secondary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis was defined as receiving any daily G-CSF starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of G-CSF support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
          <population>Full analysis set participants who received secondary prophylaxis with any daily G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="11" upper_limit="52"/>
                    <measurement group_id="O2" value="13" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="15" lower_limit="4" upper_limit="42"/>
                    <measurement group_id="O4" value="20" lower_limit="12" upper_limit="32"/>
                    <measurement group_id="O5" value="22" lower_limit="6" upper_limit="55"/>
                    <measurement group_id="O6" value="21" lower_limit="13" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Pegfilgrastim</title>
        <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received primary prophylaxis with pegfilgrastim</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Pegfilgrastim</title>
          <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
          <population>Full analysis set participants who received primary prophylaxis with pegfilgrastim</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="360"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.01" spread="0.03" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O4" value="1.00" spread="0.05" lower_limit="7" upper_limit="13"/>
                    <measurement group_id="O5" value="1.01" spread="0.03" lower_limit="3" upper_limit="24"/>
                    <measurement group_id="O6" value="1.00" spread="0.04" lower_limit="7" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Any Daily G-CSF</title>
        <description>The average number of days of daily G-CSF use per cycle was calculated across all administered cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received primary prophylaxis with any daily G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Any Daily G-CSF</title>
          <description>The average number of days of daily G-CSF use per cycle was calculated across all administered cycles.</description>
          <population>Full analysis set participants who received primary prophylaxis with any daily G-CSF</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.63"/>
                    <measurement group_id="O2" value="3.95" spread="1.18" lower_limit="8" upper_limit="42"/>
                    <measurement group_id="O3" value="4.95" spread="1.31" lower_limit="2" upper_limit="38"/>
                    <measurement group_id="O4" value="4.77" spread="1.72" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O5" value="5.85" spread="2.64" lower_limit="3" upper_limit="56"/>
                    <measurement group_id="O6" value="4.88" spread="1.84" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Pegfilgrastim</title>
        <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received secondary prophylaxis with pegfilgrastim</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Pegfilgrastim</title>
          <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
          <population>Full analysis set participants who received secondary prophylaxis with pegfilgrastim</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.00" lower_limit="16" upper_limit="61"/>
                    <measurement group_id="O3" value="1.04" spread="0.12" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="O4" value="1.02" spread="0.21" lower_limit="8" upper_limit="23"/>
                    <measurement group_id="O5" value="1.00" spread="0.00" lower_limit="12" upper_limit="65"/>
                    <measurement group_id="O6" value="1.02" spread="0.20" lower_limit="10" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Any Daily G-CSF</title>
        <description>The average number of days of daily G-CSF use per cycle was calculated across all administered cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received secondary prophylaxis with any daily G-CSF.</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Any Daily G-CSF</title>
          <description>The average number of days of daily G-CSF use per cycle was calculated across all administered cycles.</description>
          <population>Full analysis set participants who received secondary prophylaxis with any daily G-CSF.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="1.82" lower_limit="11" upper_limit="52"/>
                    <measurement group_id="O2" value="4.28" spread="0.87" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="4.04" spread="1.61" lower_limit="4" upper_limit="42"/>
                    <measurement group_id="O4" value="4.74" spread="2.64" lower_limit="12" upper_limit="32"/>
                    <measurement group_id="O5" value="3.50" spread="0.95" lower_limit="6" upper_limit="55"/>
                    <measurement group_id="O6" value="4.58" spread="2.53" lower_limit="13" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Primary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis was defined as receiving any other G-CSF starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received primary prophylaxis with other G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Primary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Primary prophylaxis was defined as receiving any other G-CSF starting in cycle 1 on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Participants who received G-CSF support from the beginning of cycle 1 were assigned to primary prophylaxis regardless of whether they continued to receive G-CSF support in subsequent cycles.</description>
          <population>Full analysis set participants who received primary prophylaxis with other G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O2" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O4" value="17" lower_limit="3" upper_limit="56"/>
                    <measurement group_id="O5" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O6" value="14" lower_limit="3" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Secondary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis was defined as receiving any daily G-CSF starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of G-CSF support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received secondary prophylaxis with other G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Secondary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Secondary prophylaxis was defined as receiving any daily G-CSF starting in cycle 2 onwards on day 1 to 7 if chemotherapy completed by day 7 and day 1 to 11 if chemotherapy completed after day 7. Assignment to G-CSF use groups was programmatically derived rather than assigned by the investigator. Participants were assigned to a G-CSF use group that represented the ‘best’ G-CSF therapy they received at any point in the study. Adherence of G-CSF support in subsequent cycles was not required for secondary prophylaxis; just an initiation of G-CSF support in the beginning of cycle 2 or later. Results include the FN event that may have triggered the secondary prophylaxis treatment.</description>
          <population>Full analysis set participants who received secondary prophylaxis with other G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="5" upper_limit="70"/>
                    <measurement group_id="O2" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O4" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O5" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O6" value="0">Not calculated when n=0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Treatment With Pegfilgrastim Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with pegfilgrastim is defined as participants who started pegfilgrastim treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received treatment with pegfilgrastim</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Treatment With Pegfilgrastim Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with pegfilgrastim is defined as participants who started pegfilgrastim treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
          <population>Full analysis set participants who received treatment with pegfilgrastim</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O2" value="0">Not calculated when n=0</measurement>
                    <measurement group_id="O3" value="0">Not calculated when n=0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Treatment With Any Daily G-CSF Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with any daily G-CSF is defined as participants who started daily G-CSF treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received treatment with any daily G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Treatment With Any Daily G-CSF Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with any daily G-CSF is defined as participants who started daily G-CSF treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
          <population>Full analysis set participants who received treatment with any daily G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="19" upper_limit="73"/>
                    <measurement group_id="O2" value="13" lower_limit="4" upper_limit="38"/>
                    <measurement group_id="O3" value="13" lower_limit="2" upper_limit="47"/>
                    <measurement group_id="O4" value="12" lower_limit="3" upper_limit="34"/>
                    <measurement group_id="O5" value="25" lower_limit="5" upper_limit="70"/>
                    <measurement group_id="O6" value="14" lower_limit="5" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Treatment With Any Other G-CSF Who Experienced Febrile Neutropenia</title>
        <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with any other G-CSF is defined as participants who started other G-CSF treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received treatment with any other G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Treatment With Any Other G-CSF Who Experienced Febrile Neutropenia</title>
          <description>FN was defined as a single oral temperature ≥ 38.3°C, or a temperature of ≥ 38.0°C for ≥ 1 hour with a neutrophil count of &lt; 500 cells/mm² or &lt; 1000 cells/mm² and predicted to fall below 500 cells/mm². Treatment with any other G-CSF is defined as participants who started other G-CSF treatment after day 7 of any cycle if chemotherapy completed by day 7 and after day 11 of any cycle if chemotherapy completed after day 7.</description>
          <population>Full analysis set participants who received treatment with any other G-CSF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100">Not calculated when n=100</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Treatment in Participants Receiving Treatment With Pegfilgrastim</title>
        <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received treatment with pegfilgrastim</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Treatment in Participants Receiving Treatment With Pegfilgrastim</title>
          <description>The average number of days of pegfilgrastim use per cycle was calculated across all administered cycles.</description>
          <population>Full analysis set participants who received treatment with pegfilgrastim</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.89"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00">Not calculated as N=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Treatment in Participants Receiving Treatment With Any Daily G-CSF</title>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants who received treatment with any daily G-CSF</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Treatment in Participants Receiving Treatment With Any Daily G-CSF</title>
          <population>Full analysis set participants who received treatment with any daily G-CSF</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="1.92" lower_limit="19" upper_limit="73"/>
                    <measurement group_id="O2" value="4.45" spread="1.18" lower_limit="4" upper_limit="38"/>
                    <measurement group_id="O3" value="2.83" spread="1.21" lower_limit="2" upper_limit="47"/>
                    <measurement group_id="O4" value="2.95" spread="1.50" lower_limit="3" upper_limit="34"/>
                    <measurement group_id="O5" value="2.38" spread="0.75" lower_limit="5" upper_limit="70"/>
                    <measurement group_id="O6" value="2.84" spread="1.39" lower_limit="5" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chemotherapy Dose Delays in Cycles 2 Through 8</title>
        <description>A dose delay is defined as a delay of more than 3 days in the start of chemotherapy measured since the start of the previous cycle. The percentage of participants with delays in chemotherapy administration are summarized by the length of delay (&gt; 3 days, &gt; 5 days, and &gt; 7 days) across cycles 2 through 8.</description>
        <time_frame>Cycles 2 - 8 (approximately 21 weeks)</time_frame>
        <population>Full analysis set participants who received more than 1 cycle of chemotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chemotherapy Dose Delays in Cycles 2 Through 8</title>
          <description>A dose delay is defined as a delay of more than 3 days in the start of chemotherapy measured since the start of the previous cycle. The percentage of participants with delays in chemotherapy administration are summarized by the length of delay (&gt; 3 days, &gt; 5 days, and &gt; 7 days) across cycles 2 through 8.</description>
          <population>Full analysis set participants who received more than 1 cycle of chemotherapy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="734"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 3 Days Delay in One or More Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="40" upper_limit="56"/>
                    <measurement group_id="O2" value="46" lower_limit="39" upper_limit="52"/>
                    <measurement group_id="O3" value="52" lower_limit="44" upper_limit="61"/>
                    <measurement group_id="O4" value="29" lower_limit="26" upper_limit="32"/>
                    <measurement group_id="O5" value="47" lower_limit="37" upper_limit="58"/>
                    <measurement group_id="O6" value="31" lower_limit="28" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 Days Delay in One or More Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="32" upper_limit="48"/>
                    <measurement group_id="O2" value="39" lower_limit="33" upper_limit="46"/>
                    <measurement group_id="O3" value="47" lower_limit="38" upper_limit="56"/>
                    <measurement group_id="O4" value="22" lower_limit="19" upper_limit="25"/>
                    <measurement group_id="O5" value="40" lower_limit="31" upper_limit="51"/>
                    <measurement group_id="O6" value="24" lower_limit="21" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 7 Days Delay in One or More Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O2" value="23" lower_limit="18" upper_limit="29"/>
                    <measurement group_id="O3" value="26" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O4" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O5" value="21" lower_limit="14" upper_limit="30"/>
                    <measurement group_id="O6" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cycles With Chemotherapy Dose Delays</title>
        <description>A dose delay is defined as a delay of &gt; 3 days in the start of chemotherapy measured since the start of the previous cycle. The percentage of cycles delayed are summarized by the length of delay (&gt; 3 days, &gt; 5 days, and &gt; 7 days) across cycles 2 through 8.</description>
        <time_frame>Cycles 2 - 8 (approximately 21 days)</time_frame>
        <population>Full analysis set participants who received more than 1 cycle of chemotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cycles With Chemotherapy Dose Delays</title>
          <description>A dose delay is defined as a delay of &gt; 3 days in the start of chemotherapy measured since the start of the previous cycle. The percentage of cycles delayed are summarized by the length of delay (&gt; 3 days, &gt; 5 days, and &gt; 7 days) across cycles 2 through 8.</description>
          <population>Full analysis set participants who received more than 1 cycle of chemotherapy</population>
          <units>percentage of cycles</units>
          <param>Number</param>
          <units_analyzed>Total cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="734"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="822"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="585"/>
                <count group_id="O3" value="473"/>
                <count group_id="O4" value="3697"/>
                <count group_id="O5" value="402"/>
                <count group_id="O6" value="4104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 3 Days Delay in One or More Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 Days Delay in One or More Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 7 Days Delay in One or More Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chemotherapy Dose Reductions</title>
        <description>A participant is considered to have a dose reduction in a given cycle if there was a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants with actual regimens as planned (17 participants received a different regimen to what was planned and are thus excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chemotherapy Dose Reductions</title>
          <description>A participant is considered to have a dose reduction in a given cycle if there was a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
          <population>Full analysis set participants with actual regimens as planned (17 participants received a different regimen to what was planned and are thus excluded)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="732"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="27" upper_limit="42"/>
                    <measurement group_id="O2" value="25" lower_limit="20" upper_limit="31"/>
                    <measurement group_id="O3" value="22" lower_limit="16" upper_limit="30"/>
                    <measurement group_id="O4" value="16" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O5" value="29" lower_limit="21" upper_limit="39"/>
                    <measurement group_id="O6" value="17" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cycles With Chemotherapy Dose Reductions</title>
        <description>A dose reduction in a given cycle is defined as a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants with actual regimens as planned (17 participants received a different regimen to what was planned and are thus excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cycles With Chemotherapy Dose Reductions</title>
          <description>A dose reduction in a given cycle is defined as a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
          <population>Full analysis set participants with actual regimens as planned (17 participants received a different regimen to what was planned and are thus excluded)</population>
          <units>percentage of cycles</units>
          <param>Number</param>
          <units_analyzed>Total cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="732"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="822"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="791"/>
                <count group_id="O3" value="610"/>
                <count group_id="O4" value="4399"/>
                <count group_id="O5" value="486"/>
                <count group_id="O6" value="4891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="27" upper_limit="42"/>
                    <measurement group_id="O2" value="13" lower_limit="20" upper_limit="31"/>
                    <measurement group_id="O3" value="12" lower_limit="16" upper_limit="30"/>
                    <measurement group_id="O4" value="6" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O5" value="16" lower_limit="21" upper_limit="39"/>
                    <measurement group_id="O6" value="7" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Cycles With &gt; 3 Days Chemotherapy Dose Delays in Cycles 2 to 8</title>
        <description>A dose delay is defined as a delay of &gt; 3 days in the start of chemotherapy measured since the start of the previous cycle.</description>
        <time_frame>Cycles 2 - 8 (approximately 21 weeks)</time_frame>
        <population>Full analysis set participants who received more than 1 cycle of chemotherapy and had &gt; 3 days delay in one or more cycles</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Cycles With &gt; 3 Days Chemotherapy Dose Delays in Cycles 2 to 8</title>
          <description>A dose delay is defined as a delay of &gt; 3 days in the start of chemotherapy measured since the start of the previous cycle.</description>
          <population>Full analysis set participants who received more than 1 cycle of chemotherapy and had &gt; 3 days delay in one or more cycles</population>
          <units>cycles</units>
          <param>Number</param>
          <units_analyzed>Cycles with &gt; 3 days delay</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cycles with &gt; 3 days delay</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="268"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Febrile Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy Induced Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy Induced Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy Induced Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Hematological Reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Non-Hematological Reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Administration Error</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Cycles With ≥ 15% Chemotherapy Dose Reductions in Cycles 1-8</title>
        <description>A dose reduction in a given cycle is defined as a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set participants with actual regimens as planned and with ≥ 15% chemotherapy dose reduction in any cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Cycles With ≥ 15% Chemotherapy Dose Reductions in Cycles 1-8</title>
          <description>A dose reduction in a given cycle is defined as a ≥ 15% reduction in dose of any chemotherapy agent planned for that cycle, relative to the dose planned at the baseline visit for that cycle.</description>
          <population>Full analysis set participants with actual regimens as planned and with ≥ 15% chemotherapy dose reduction in any cycle.</population>
          <units>cycles</units>
          <param>Number</param>
          <units_analyzed>Cycles with ≥ 15% dose reduction</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cycles with ≥ 15% dose reduction</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="256"/>
                <count group_id="O5" value="77"/>
                <count group_id="O6" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="27" upper_limit="42"/>
                    <measurement group_id="O2" value="4" lower_limit="20" upper_limit="31"/>
                    <measurement group_id="O3" value="3" lower_limit="16" upper_limit="30"/>
                    <measurement group_id="O4" value="15" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O5" value="6" lower_limit="21" upper_limit="39"/>
                    <measurement group_id="O6" value="21" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy induced neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy induced anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy induced thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other hematological reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other non-hematological reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose administration error</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced to assess dose/tolerability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="109"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Anti-infective Use in Cycles 1 to 8</title>
        <description>Number of participants with systemic anti-infective use, including antibiotics, anti-fungal and virostatic for prophylaxis or treatment.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Anti-infective Use in Cycles 1 to 8</title>
          <description>Number of participants with systemic anti-infective use, including antibiotics, anti-fungal and virostatic for prophylaxis or treatment.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="198"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unplanned Hospitalizations</title>
        <description>Unplanned hospitalizations included only those which involved an overnight stay and occurred in cycles 1 to 8.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unplanned Hospitalizations</title>
          <description>Unplanned hospitalizations included only those which involved an overnight stay and occurred in cycles 1 to 8.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="107"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessed Clinical Response at End of Treatment</title>
        <time_frame>End of treatment (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessed Clinical Response at End of Treatment</title>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="218"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease/No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="383"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematological Toxicities</title>
        <description>The number of participants experiencing treatment related grade 3 and 4 hematological toxicities during cycles 1 to 8. Participants experiencing both Grade 3 and Grade 4 toxicities are reported under Grade 4 only (maximum toxicity). Toxicity grades for hematology data are defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0: Absolute neutrophil count (ANC) - Grade 3: &lt; 1.0 - 0.5 x 10^9/L; ANC - Grade 4: &lt; 0.5 x 10^9/L; White blood cells (WBC) - Grade 3: &lt; 2.0 - 1.0 x 10^9/L; WBC - Grade 4: &lt; 1.0 x 10^9/L; Hemoglobin - Grade 3: &lt; 8.0 - 6.5 g/dL; Hemoglobin - Grade 4: &lt; 6.5 g/dL; Platelets - Grade 3: &lt; 50 - 25 x 10^9/L; Platelets - Grade 4: &lt; 25 x 10^9/L.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematological Toxicities</title>
          <description>The number of participants experiencing treatment related grade 3 and 4 hematological toxicities during cycles 1 to 8. Participants experiencing both Grade 3 and Grade 4 toxicities are reported under Grade 4 only (maximum toxicity). Toxicity grades for hematology data are defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0: Absolute neutrophil count (ANC) - Grade 3: &lt; 1.0 - 0.5 x 10^9/L; ANC - Grade 4: &lt; 0.5 x 10^9/L; White blood cells (WBC) - Grade 3: &lt; 2.0 - 1.0 x 10^9/L; WBC - Grade 4: &lt; 1.0 x 10^9/L; Hemoglobin - Grade 3: &lt; 8.0 - 6.5 g/dL; Hemoglobin - Grade 4: &lt; 6.5 g/dL; Platelets - Grade 3: &lt; 50 - 25 x 10^9/L; Platelets - Grade 4: &lt; 25 x 10^9/L.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 absolute neutrophil count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 absolute neutrophil count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 white blood cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 white blood cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time to disease progression was calculated from cycle 1 day 1 to a date at which disease progression was first recorded. Participants who died due to causes other than disease progression were censored at the date of death. Participants who were alive and whose disease had not progressed at the most recent contact, or who were lost to follow-up, or with missing data, were censored at the date of last contact. Median time to disease progression was estimated from the Kaplan-Meier survival function.</description>
        <time_frame>From cycle 1, day 1 until end of the long-term follow-up; median time on follow-up from cycle 1, day 1 was 52 months.</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to disease progression was calculated from cycle 1 day 1 to a date at which disease progression was first recorded. Participants who died due to causes other than disease progression were censored at the date of death. Participants who were alive and whose disease had not progressed at the most recent contact, or who were lost to follow-up, or with missing data, were censored at the date of last contact. Median time to disease progression was estimated from the Kaplan-Meier survival function.</description>
          <population>Full analysis set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="9.9" upper_limit="16.4"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.5" upper_limit="7.8"/>
                    <measurement group_id="O3" value="6.8" lower_limit="6.4" upper_limit="7.9"/>
                    <measurement group_id="O4" value="NA">Not estimable due to the low number of events</measurement>
                    <measurement group_id="O5" value="11.8" lower_limit="9.1" upper_limit="16.4"/>
                    <measurement group_id="O6" value="NA">Not estimable due to the low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Treatment With Erythropoiesis-stimulating Agents (ESAs)</title>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Participants who received treatment with an ESA</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment With Erythropoiesis-stimulating Agents (ESAs)</title>
          <population>Participants who received treatment with an ESA</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reason for Treatment With Erythropoiesis-stimulating Agents</title>
        <description>The reason treatment with an ESA was initiated as recorded by the investigator; participants may have more than one reason for initiating treatment.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Participants who received treatment with an ESA</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Reason for Treatment With Erythropoiesis-stimulating Agents</title>
          <description>The reason treatment with an ESA was initiated as recorded by the investigator; participants may have more than one reason for initiating treatment.</description>
          <population>Participants who received treatment with an ESA</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk of chemotherapy induced anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evidence based guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other anemia-related symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level at Initiation of Erythropoiesis-stimulating Agent Treatment</title>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Participants who received treatment with an ESA</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level at Initiation of Erythropoiesis-stimulating Agent Treatment</title>
          <population>Participants who received treatment with an ESA</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin &lt; 9 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin 9 - 11 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin &gt; 11 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinical Visits in Cycles 1-8 by ESA Use</title>
        <description>The average number of clinical visits per month (28 day period) during cycles 1 to 8 and during the period of ESA treatment in cycles 1 to 8.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Any ESA Use</title>
            <description>Participants who received treatment with any erythropoiesis-stimulating agent (ESA) during cycles 1 to 8.</description>
          </group>
          <group group_id="O2">
            <title>No ESA Use</title>
            <description>Participants who did not receive treatment with a erythropoiesis-stimulating agent (ESA) during cycles 1 to 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinical Visits in Cycles 1-8 by ESA Use</title>
          <description>The average number of clinical visits per month (28 day period) during cycles 1 to 8 and during the period of ESA treatment in cycles 1 to 8.</description>
          <population>Full analysis set</population>
          <units>visits per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visits per month during cycles 1 - 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.6"/>
                    <measurement group_id="O2" value="2.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visits per month during period of ESA treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.2"/>
                    <measurement group_id="O2" value="NA">Participants in this group did not receive any ESA treatment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Required a Red Blood Cell (RBC) Transfusion After 5 Weeks of ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants with RBC transfusions from five weeks post initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Required a Red Blood Cell (RBC) Transfusion After 5 Weeks of ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants with RBC transfusions from five weeks post initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="4.6" lower_limit="3" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin During ESA Treatment Phase</title>
        <time_frame>Initiation of ESA treatment (last assessment on or prior to ESA day 1) and at end of ESA treatment; median duration of ESA treatment was 4 weeks, maximum was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA and with hemoglobin measurements available at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin During ESA Treatment Phase</title>
          <population>Participants who received treatment with an ESA and with hemoglobin measurements available at both time points.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hematopoietic Response</title>
        <description>Kaplan-Meier estimate of the percentage of participants in cycles 1 to 8 receiving ESA treatment who achieved a hematopoietic response during the ESA treatment phase, defined as a hemoglobin concentration ≥ 12 g/dL or a ≥ 2 g/dL rise in hemoglobin after starting ESA treatment.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Participants who received treatment with an ESA</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hematopoietic Response</title>
          <description>Kaplan-Meier estimate of the percentage of participants in cycles 1 to 8 receiving ESA treatment who achieved a hematopoietic response during the ESA treatment phase, defined as a hemoglobin concentration ≥ 12 g/dL or a ≥ 2 g/dL rise in hemoglobin after starting ESA treatment.</description>
          <population>Participants who received treatment with an ESA</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="4.6" lower_limit="29" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 9 g/dL After 5 Weeks ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 9 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA and with hemoglobin &lt; 9 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 9 g/dL After 5 Weeks ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 9 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA and with hemoglobin &lt; 9 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="4.6" lower_limit="-1" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 10 g/dL After 5 Weeks ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 10 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 10 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 10 g/dL After 5 Weeks ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 10 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 10 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="4.6" lower_limit="61" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 11 g/dL After 5 Weeks ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 11 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 11 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 11 g/dL After 5 Weeks ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 11 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 11 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" spread="4.6" lower_limit="51" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 12 g/dL After 5 Weeks ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 12 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 12 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 12 g/dL After 5 Weeks ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level ≥ 12 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 12 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="4.6" lower_limit="17" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL After 5 Weeks ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level from 10 to 12 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 10 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL After 5 Weeks ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level from 10 to 12 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 10 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="4.6" lower_limit="58" upper_limit="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 12 to 13 g/dL After 5 Weeks ESA Treatment</title>
        <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level from 12 to 13 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
        <time_frame>From 5 weeks post initiation of ESA treatment to the end of ESA treatment phase (EOTP) during cycles 1 - 8; maximum duration of ESA treatment was 23 weeks.</time_frame>
        <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 12 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 12 to 13 g/dL After 5 Weeks ESA Treatment</title>
          <description>Kaplan-Meier estimate of the percentage of participants achieving a hemoglobin level from 12 to 13 g/dL during the period from five weeks after initiation of ESA treatment until the end of ESA treatment during cycles 1 to 8.</description>
          <population>Participants who received treatment with an ESA, and with hemoglobin &lt; 12 g/dL at initiation of ESA treatment and still on study 5 weeks after initiation of ESA treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="4.6" lower_limit="15" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL 9 Weeks After Initiation of ESA Treatment</title>
        <description>The percentage of participants achieving a hemoglobin level from 10 to 12 g/dL after 9 weeks of ESA treatment.</description>
        <time_frame>9 weeks post initiation of ESA treatment</time_frame>
        <population>Participants who received treatment with an ESA</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Participants diagnosed with breast, ovarian, or lung cancer and receiving myelotoxic chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL 9 Weeks After Initiation of ESA Treatment</title>
          <description>The percentage of participants achieving a hemoglobin level from 10 to 12 g/dL after 9 weeks of ESA treatment.</description>
          <population>Participants who received treatment with an ESA</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="4.6" lower_limit="10" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Transfusions in Cycles 1 to 8</title>
        <description>Number of participants who received transfusions, including platelets, packed red blood cells, whole blood, or other, during cycles 1 to 8.</description>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Transfusions in Cycles 1 to 8</title>
          <description>Number of participants who received transfusions, including platelets, packed red blood cells, whole blood, or other, during cycles 1 to 8.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Transfusions Per Participant in Cycles 1 to 8</title>
        <time_frame>Cycles 1 - 8 (approximately 24 weeks)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ovarian</title>
            <description>Participants diagnosed with ovarian cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>NSCLC</title>
            <description>Participants diagnosed with non-small cell lung cancer (NSCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>SCLC</title>
            <description>Participants diagnosed with small cell lung cancer (SCLC) and receiving chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Breast Stage I-III</title>
            <description>Participants diagnosed with Stage I-III breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O5">
            <title>Breast Metastatic</title>
            <description>Participants diagnosed with metastatic breast cancer and receiving chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Breast Total</title>
            <description>Participants diagnosed with breast cancer (any stage) and receiving chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Transfusions Per Participant in Cycles 1 to 8</title>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="738"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="713"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2 Transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 24 weeks (8 treatment cycles)</time_frame>
      <desc>Only adverse drug reactions (ADRs) considered by the investigator to be related to Amgen products were collected. Any ADRs relating to pegfilgrastim, filgrastim, and darbepoetin alfa are reported.
Other Adverse Events summarizes the non-serious occurrences of ADRs that exceed the 5% frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ovarian</title>
          <description>Ovarian Cancer</description>
        </group>
        <group group_id="E2">
          <title>NSCLC</title>
          <description>Non-small Cell Lung Cancer</description>
        </group>
        <group group_id="E3">
          <title>SCLC</title>
          <description>Small Cell Lung Cancer</description>
        </group>
        <group group_id="E4">
          <title>Breast Stage I-III</title>
          <description>Breast Cancer, Stages I-III</description>
        </group>
        <group group_id="E5">
          <title>Breast Metastatic</title>
          <description>Breast Cancer, Metastatic</description>
        </group>
        <group group_id="E6">
          <title>Breast Total</title>
          <description>All Breast Cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="738"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="829"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="738"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="829"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="738"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="829"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="738"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="829"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="738"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="829"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="738"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="829"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

